A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Phase of Trial: Phase III
Latest Information Update: 17 Oct 2017
At a glance
- Drugs Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms ARCHES
- Sponsors Astellas Pharma
- 15 Aug 2017 Planned End Date changed from 30 Dec 2023 to 1 Dec 2023.
- 15 Aug 2017 Planned primary completion date changed from 30 Apr 2020 to 1 Apr 2020.
- 10 Jun 2017 Biomarkers information updated